51 related articles for article (PubMed ID: 2404581)
1. Experimental studies of radioimmunodetection of cancer: an overview.
Sands H
Cancer Res; 1990 Feb; 50(3 Suppl):809s-813s. PubMed ID: 2404581
[TBL] [Abstract][Full Text] [Related]
2. Physiology of monoclonal antibody accretion by tumors.
Sands H; Jones PL
Cancer Treat Res; 1990; 51():97-122. PubMed ID: 1977461
[TBL] [Abstract][Full Text] [Related]
3. [Recent progress in radioimmunodetection for cancer using radio-labeled monoclonal antibodies].
Toshihiko K; Nobuko I; Shigenobu N; Tatsuo M; Keisuke N
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2230-41. PubMed ID: 6194758
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies: new agents for cancer detection and targeted therapy.
Baldwin RW; Byers VS
Cancer Detect Prev; 1991; 15(2):133-6. PubMed ID: 2032254
[TBL] [Abstract][Full Text] [Related]
5. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain RK
Cancer Res; 1990 Feb; 50(3 Suppl):814s-819s. PubMed ID: 2404582
[TBL] [Abstract][Full Text] [Related]
6. Lack of radioimmunodetection and complications associated with monoclonal anticarcinoembryonic antigen antibody cross-reactivity with an antigen on circulating cells.
Dillman RO; Beauregard JC; Sobol RE; Royston I; Bartholomew RM; Hagan PS; Halpern SE
Cancer Res; 1984 May; 44(5):2213-8. PubMed ID: 6713409
[TBL] [Abstract][Full Text] [Related]
7. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization.
Ullén A; Sandström P; Ahlström KR; Sundström B; Nilsson B; Arlestig L; Stigbrand T
Cancer Res; 1995 Dec; 55(23 Suppl):5868s-5873s. PubMed ID: 7493362
[TBL] [Abstract][Full Text] [Related]
8. From monoclonal antibodies to peptides and molecular recognition units: an overview.
Serafini AN
J Nucl Med; 1993 Mar; 34(3 Suppl):533-6. PubMed ID: 8441052
[TBL] [Abstract][Full Text] [Related]
9. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
[TBL] [Abstract][Full Text] [Related]
10. Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.
Pimm MV
Crit Rev Ther Drug Carrier Syst; 1988; 5(3):189-227. PubMed ID: 3060267
[TBL] [Abstract][Full Text] [Related]
11. Antibody-guided radiation therapy of cancer.
Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
[TBL] [Abstract][Full Text] [Related]
12. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
13. Pretargeting with labeled bivalent peptides allowing the use of four radionuclides: (111)In, (131)I, (99m)Tc, and (188)Re.
van Schaijk FG; Oosterwijk E; Soede AC; Oyen WJ; McBride WJ; Griffiths GL; Goldenberg DM; Corstens FH; Boerman OC
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3880S-5S. PubMed ID: 14506186
[TBL] [Abstract][Full Text] [Related]
14. Improved targeting of pancreatic cancer: experimental studies of a new bispecific antibody, pretargeting enhancement system for immunoscintigraphy.
Cardillo TM; Karacay H; Goldenberg DM; Yeldell D; Chang CH; Modrak DE; Sharkey RM; Gold DV
Clin Cancer Res; 2004 May; 10(10):3552-61. PubMed ID: 15161715
[TBL] [Abstract][Full Text] [Related]
15. Improved tumor targeting by combined use of two antitenascin antibodies.
Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
[TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.
Ford CH; Casson AG
Cancer Chemother Pharmacol; 1986; 17(3):197-208. PubMed ID: 3527466
[TBL] [Abstract][Full Text] [Related]
17. Tracking Antibody Distribution with Near-Infrared Fluorescent Dyes: Impact of Dye Structure and Degree of Labeling on Plasma Clearance.
Cilliers C; Nessler I; Christodolu N; Thurber GM
Mol Pharm; 2017 May; 14(5):1623-1633. PubMed ID: 28294622
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.
Conner KP; Rock BM; Kwon GK; Balthasar JP; Abuqayyas L; Wienkers LC; Rock DA
Drug Metab Dispos; 2014 Nov; 42(11):1906-13. PubMed ID: 25209366
[TBL] [Abstract][Full Text] [Related]
19. Tumor radioimmunoimaging of chimeric antibody in nude mice with hepatoma xenograft.
Gong Y; Liu KD; Zhou G; Xue Q; Chen SL; Tang ZY
World J Gastroenterol; 1998 Feb; 4(1):7-9. PubMed ID: 11819217
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral injection of an adriamycin immunoconjugate against human pancreatic cancer xenografts.
Kondo Y; Chung YS; Sawada T; Inui A; Yamashita Y; Hirayama K; Nakata B; Ho JJ; Kim YS; Sowa M
Jpn J Cancer Res; 1995 Nov; 86(11):1072-9. PubMed ID: 8567399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
